Latest Entries »

In Silico Genesis signed up a Confidential Disclosure Agreement with Public Health England (PHE), previously Health Protection Agency, in June 2013. This CDA was reaffirming an initial CDA placed in October, 2011 between Health Protection Agency (HPA) and In Silico Genesis (ISG) about the antiviral work in collaboration. 

Public Health England (PHE) https://www.gov.uk/government/organisations/public-health-england

Advertisements

In Silico Genesis presented our Alzheimer’s strategy to the One Nucleus CNS Leadership Seminar Series held in London, on the 11th of Feb. 2013.

isg_on2

This seminar will look at:

• The Prime Minister’s Dementia Challenge
• Pharmacotherapy for Alzheimer’s disease – progress and prospects
• The emerging scientific advances that may enable greater success in the future

Agenda:

10.30 – Registration

11.00 – Welcome from the Chair
Janet Knowles, Partner, Eversheds

11.10 – The Prime Minister’s Dementia Challenge
Mark Treherne, CEO, Life Sciences Investment Organisation, UKTI

11.30 – What are the prospects of slowing the progression of Alzheimer’s disease?
Prof Alan Palmer, Director MS Therapeutics

12.00 – What insights do biomarkers provide into the recent Phase III failures?
Andrea Les, Senior Imaging Scientist, IXICO

12.20 – Q&A with the speakers

12.45 – Networking Lunch

13.45 – Introduction from the Chair
Philip Oliver

13.45 Is there a future for the amyloid theory in treating Alzheimer’s disease?
Eric Karran, Alzheimer’s Research UK

14.05 Targeting Tau hyperphosporylation in AD
Ian Pike, COO, Proteome Sciences

14.25 – Genetic basis of Alzheimer disease susceptibility
Prof. Julie Williams, Cardiff University School of Medicine

14.45 – FGL Peptides as neuroprotectives in AD
Steve Rees, COO, ENKAM Pharmaceuticals A/S

15.05 – Translational genomic medicine and companion diagnostic development
Kimberley Treherne
(then, Williams), In Silico Genesis

15.25 – Closing Remarks from one Nucleus
Tony Jones, Director of Business Development, One Nucleus

15.30 – Networking drinks

16.30 – Close

Shown above can be found at http://onenucleus.com/onenucleus-events?id=692.

An Ion Channel Database – Annotation via Homology Modelling

This is an electronic copy of poster presentation at Cold Spring Harbor Laboratory conference jointed held with the Wellcome Trust Genome Campus in Hinxton, England. It is welcome for anyone to view the work via clicking the link or to download a copy of the digital version of this presentation.

It briefly addresses the construction of genomic database (of ion channel proteins, in this case), which focused particularly on potassium channels and nicotinic acetylcholine receptors. Target sequences of interest can be studied further to understand how they may function biologically, by means of pairwise alignment (2D) and computational models (3D) provided any significant homology detected from the previous alignment.

VF_ISGIn Silico Genesis Ltd presented at Venturefest Oxford 2013, at the request of Oxfordshire Bioscience Network (OBN) to represent the regional biocluster at OBN BioElevator session. This took place in Lecture Theatre 5, SAID Business School of Oxford University on Tuesday, 18th of June, 2013. The session was chaired by the chairman of the Oxfordshire Bioscience Network and attended by the CEO of OBN, Dr. Jon Rees.

In the runner-up to BioTrinity/Venturefest Oxford 2013, In Silico Genesis Limited was also approached by the OBN, about supporting a governmental initiative for the field of Life Sciences in the United Kingdom. In brief, the OBN gave me an opportunity to work with the Office of Life Sciences (OLS). Enclosed is a letter IMG_0001, forwarded to me by the OBN, from the Treasury of Her Majesty’s government. I am thankful to SAID Business School (http://www.sbs.ox.ac.uk/) of the University of Oxford for having taught me and guided me in this entrepreneurial journey,  during my biochemistry/bioinformatics work undertaken at Oxford. Thank you Oxford for everything you taught me. From Kimberley Treherne, xxx

In Silico Genesis signed up a Confidential Disclosure Agreement with Owen Mumford (www.owenmumford.com), a local manufacturing company based in Woodstock, Oxfordshire in September 2012. This two way CDA was put in place following an initial discussion on a malaria companion diagnostics device.

A closer look at how the digital images are generated.

Upon clicking the link above, you should be able either to view or to download this ppt file, which is simply a poster presentation prepared a while ago for a conference held in Naples, Italy. Hopefully, it may come closer to you how medical genomics can be related to developing good computational models of therapeutic (or scientific) interest, should you get a moment to have a look at this digital version of the poster presentation.

Find us @insilicogenesis at https://twitter.com.

ISG will produce abundant cash flow in order to return:

we commit ourselves to give 1/10 of whatever profits back, sharing the overflowing and exceeding goodness of God with others on this planet; contact@trehernefoundation.org.

 

 

An example of screening genomes from the bottom of the evolutionary hierarchy to the very top, homo sapiens, as it is currently believed to be.

This work focuses on ion channels as the majority of therapeutic targets are known to be either families of membrane proteins or those conducting regulatory functions to them.

Once the system is in place, it only requires a representative input sequence to scan the same genomic space, in order to identify putative targets of the disease associated with the initial input.

Having said that, this step is merely the start of discovery process. Medical statistics will take a strong hold during the stage of development. More to come!

 

 

Computational docking analysis This is a snapshot of two adjacent monomers of a pentameric protein called nicotinic Acetyl choline receptor. It is a computational model built on pairwise homology comparison, which was in fact done quite a while ago.

What is shown is part of an N terminal domain connected to its integral membrane protein. In this case, there is a ring-like structure made of five constituent monomer, whilst a drug ( or a small molecule, if you would like) would bind in a pocket formed in between two neighbouring ones.

It is helpful for understanding how the small molecules may bind & pass through the gate-keepers on the membrane, in order for them to be delivered into the cells.

Homology modelling is relatively straightforward, as long as there is an available 3D structure, readily determined and an identified target (for instance via medical genomics, though there can also be other ways) and a good homology comparison between the two, with some luck and skill.